Fosamax Linked to Osteonecrosis of the Jaw: Understanding Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of General Health and Science Information

The legacy of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this broad context, the dissemination of knowledge regarding pharmaceutical safety and adverse effects has been a central pillar, enabling individuals to make informed decisions about their well-being. Historically, this domain has focused on communicating risks associated with medication use in a manner accessible to diverse audiences, emphasizing the balance between therapeutic benefits and potential harms. As this heritage evolves, a natural progression emerges toward examining specific exposure scenarios that may amplify risk beyond the general patient population. The transition from broad health communication to targeted occupational concern becomes particularly relevant when considering agents like Fosamax, a bisphosphonate widely prescribed for bone disorders. While general health information has addressed the drug’s association with osteonecrosis of the jaw in clinical settings, the focus now shifts to environments where exposure may occur under different conditions—namely, occupational contexts. In manufacturing, handling, or disposal of such pharmaceuticals, workers may encounter the compound through inhalation, dermal contact, or accidental ingestion, raising distinct questions about exposure thresholds and cumulative risk. This pivot does not presuppose mechanistic pathways but rather acknowledges that occupational settings introduce variables—such as frequency, duration, and route of exposure—that warrant separate consideration from therapeutic use. Thus, the transition from general health information to occupational exposure concern is a logical extension, grounded in the principle that risk communication must adapt to diverse exposure contexts.

Bridge to Occupational Exposure Concerns

Building on the foundational understanding of Fosamax's risks in clinical populations, it is essential to consider how occupational exposure may present unique challenges. Workers involved in the manufacturing, handling, or disposal of Fosamax may be exposed through inhalation, dermal contact, or accidental ingestion, leading to potential systemic effects. While the therapeutic use of Fosamax involves controlled dosing and monitoring, occupational exposure can be variable and unmonitored, raising concerns about cumulative risk and long-term health effects. This section explores the evidence linking Fosamax to osteonecrosis of the jaw (ONJ) and examines how occupational exposure scenarios might influence risk assessment.

Fosamax and Osteonecrosis of the Jaw: Evidence and Mechanisms

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse event: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves bone exposure in the oral cavity, often accompanied by pain, swelling, and infection, and diagnosis is typically made through clinical examination and imaging. The pharmacological mechanism of Fosamax involves inhibition of bone resorption by osteoclasts, which reduces bone turnover. This action, while beneficial for increasing bone mass and reducing fracture risk in osteoporosis, may contribute to the development of ONJ. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate, has provided information that can help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Research using estrogen-deficient rats treated with alendronate has examined effects on the jawbone, including mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These studies suggest that bisphosphonate treatment alters the mechanical and structural properties of jawbone, potentially predisposing it to necrosis. The mechanistic pathways linking Fosamax to ONJ are not fully understood but are believed to involve suppression of bone remodeling, leading to accumulation of microdamage and reduced ability to repair bone. Additionally, bisphosphonates may impair blood supply to the jawbone and affect the function of oral mucosal cells.

Risk Factors and Warnings for ONJ

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the warning does not provide specific guidance on the optimal duration of use to minimize ONJ risk, and the limitations of use section states that the optimal duration of use has not been determined, with a suggestion to consider drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and Temporal Relationship

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse event, its incidence in clinical trials was not significantly elevated compared to placebo, indicating that other factors, such as underlying risk factors, may play a role. The timeline between exposure and documented harm can vary widely. ONJ has been reported in patients taking bisphosphonates, including Fosamax, and the risk may increase with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the onset of symptoms can occur as early as one day after starting the drug, though this is likely rare and may represent a different mechanism (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients who develop ONJ, the condition can be challenging to treat, and management often involves discontinuation of the bisphosphonate, antibiotic therapy, and surgical debridement.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The mechanism involves suppression of bone remodeling, leading to microdamage accumulation and impaired repair. Animal studies have shown altered mechanical properties of jawbone after alendronate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ from Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ to develop after starting Fosamax?

The time to onset of ONJ symptoms can vary from one day to several months after starting the drug. Most patients experience relief after stopping the drug, and recurrence may occur upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.